João L. Carapinha

Overview of NICE’s Elranatamab Managed Access Agreement
HIQA’s Strategic Blueprint for Health Care Excellence: Draft Corporate ...
Rifaximin Use Linked to Daptomycin Resistance: Implications for Antibiotic St...
NICE Rejects Donanemab for NHS Use Due to Cost Concerns
Innovative Pricing and Payment Models for Health Technologies
Draft European Medicines Agency Strategy 2028: Enhancing Accessibility and In...